Conference abstractPublished 14 Nov 2016
Efficacy and Safety of a Nutritional Supplement Combination on Dyslipidemia and Cardiovascular Inflammatory Markers
Vanderbilt University School of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This study was a randomized, double-blind, placebo-controlled and single-center trial of 40 patients, consisting of a screening visit, a 2-week run-in, and a 4-month treatment period with a combination nutritional supplement (LC). Advanced lipid testing and advanced cardiovascular inflammatory markers were measured. LC® significantly reduced total cholesterol, LDL-C, VLDL-C, ox LDL, ApoB, TG, LDL-P, heart rate and diastolic blood pressure and increased HDL-P and increased LDL size compared to placebo at one month and four months. In addition, LC® significantly reduced hs-CRP, TNF alpha, IL-6 within the treatment group from baseline. There were no adverse effects in the treatment group. LC® did not lower Co enzyme Q 10 levels or adversely affect any other lab parameters that were measured. These changes would be expected to reduce cardiovascular risk. LC® is an effective and safe alternative to statins and other lipid- lowering drugs in the treatment of dyslipidemia.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectCardiology
- SubjectNutrition & Food Science
- BylineArticles whose byline prints “Mark Houston”